Mersinol

Escitalopram, the active ingredient in Mersinol, is a selective serotonin reuptake inhibitor (SSRI) presented as an oral tablet for oral use. It treats major depressive disorder, generalized anxiety disorder, social anxiety disorder and panic disorder in adult patients.

GNH USA supplies Mersinol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Escitalopram acts on the serotonergic pathway and is indicated for several mood and anxiety disorders.

Major depressive disorder: improves mood, energy and functional capacity. Generalized anxiety disorder: reduces excessive worry and physical tension. Social anxiety disorder: lessens fear of social situations and improves interpersonal confidence. Panic disorder: decreases the frequency and intensity of panic attacks.

Escitalopram may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset often occurring early in therapy. - Headache: transient tension‑type headaches reported by many patients. - Insomnia: difficulty initiating or maintaining sleep.

Serious or Rare Side Effects: - Serotonin syndrome: potentially life‑threatening condition with agitation, hyperthermia and neuromuscular abnormalities. - Suicidal thoughts: increased risk especially during the initial treatment period. - Severe allergic reaction: rash, swelling, or anaphylaxis requiring immediate medical attention.

Before initiating escitalopram, clinicians should consider several safety aspects.

Assess suicidality: evaluate for depressive ideation, especially in the first weeks. Monitor for serotonin syndrome: watch for signs of hyperthermia, rigidity, or autonomic instability. Use caution in hepatic impairment: dose adjustments may be needed. Avoid abrupt discontinuation: taper gradually to reduce withdrawal symptoms. Review concomitant serotonergic agents: assess interaction risk. Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Escitalopram can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Pimozide: may cause QT prolongation and cardiac arrhythmias. - Thioridazine: increased risk of cardiac conduction abnormalities.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): heightened bleeding risk. - Anticoagulants (e.g., warfarin): may enhance anticoagulant effect. - Triptans: potential for additive serotonergic effects. - Carbamazepine: may reduce escitalopram plasma levels. - Alcohol: can exacerbate central nervous system depression.